Anticonvulsant. Inhibits glutamate release, possibly through inhibition of Na+, K+ and Ca2+ currents. Also blocks heterologously expressed and native α4β2 nAChRs with a similar affinity to Na+ channels.
Water-soluble Salt also available.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 256.09. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.9 mL||19.52 mL||39.05 mL|
|5 mM||0.78 mL||3.9 mL||7.81 mL|
|10 mM||0.39 mL||1.95 mL||3.9 mL|
|50 mM||0.08 mL||0.39 mL||0.78 mL|
References are publications that support the biological activity of the product.
Grunze et al (1998) Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38 131 PMID: 9778600
Leach et al (1991) Neurochemical and behavioral aspects of lamotrigine. Epilepsia 32 S4 PMID: 1685439
Zheng et al (2010) The anticonvulsive drug lamotrigine blocks neuronal α4β2 nicotinic acetylcholine receptors. J.Pharmacol.Exp.Ther. 335 401 PMID: 20688974
Zona and Avoli (1997) Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38 522 PMID: 9184596
If you know of a relevant reference for Lamotrigine, please let us know.
View Related Products by Target
Keywords: Lamotrigine, Lamotrigine supplier, inhibitors, glutamate, release, Anticonvulsant, Blocks, Na+, K+, Ca2+, calcium, sodium, potassium, channels, inhibits, Glutamate, mGlur, Receptors, Metabotropic, iGluR, Ionotropic, Channel, modulators, VDAC, GlaxoSmithKline, GSK, Miscellaneous, Other, Modulators, 1611, Tocris Bioscience
2 Citations for Lamotrigine
Citations are publications that use Tocris products. Selected citations for Lamotrigine include:
Kashyap et al (2015) Characterization of the role of HCN channels in β3-adrenoceptor mediated rat bladder relaxation. J Neurosci 2 PMID: 26709376
Lazar et al (2015) Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway. Front Pharmacol 6 210 PMID: 26441665
Do you know of a great paper that uses Lamotrigine from Tocris? Please let us know.
Reviews for Lamotrigine
There are currently no reviews for this product. Be the first to review Lamotrigine and earn rewards!
Have you used Lamotrigine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.